Pharvaris N.V. SEC Filings

Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Pharvaris N.V. (PHVS) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Pharvaris files annual reports on Form 20-F and furnishes interim updates on Form 6-K under the Securities Exchange Act of 1934, providing investors with information on its late-stage biopharmaceutical operations and capital markets activity.

Through Forms 6-K, Pharvaris furnishes press releases on financial results and business updates, including quarterly IFRS-based financial statements, management’s discussion and analysis, and details on cash runway and research and development spending. These filings also cover outcomes of the company’s Annual General Meeting of Shareholders, auditor appointments, and board-related matters.

Filings related to capital raising and securities include descriptions of underwritten public offerings of ordinary shares and pre-funded warrants, underwriting agreements, pre-funded warrant terms, and associated legal opinions. For example, Pharvaris has used an effective shelf registration statement on Form F-3 and Form F-3ASR to register offerings that fund late-stage clinical programs, commercialization preparation, and general corporate purposes.

For its core therapeutic focus, investors can use Pharvaris filings alongside AI-powered summaries to understand disclosures around clinical development of deucrictibant for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). While detailed clinical data are often first released via press releases, they are also referenced in 6-K reports that are incorporated by reference into the company’s registration statements.

Stock Titan’s tools can help interpret these documents by highlighting key points from lengthy exhibits, such as interim financial statements, registration rights agreements, and offering documentation. Real-time updates from EDGAR, combined with AI-generated explanations, allow users to quickly review new Pharvaris filings, track how the company finances its late-stage pipeline, and monitor changes in its registered securities.